Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 US Oncology, BioMarin Partner on Phase III BMN 673 Study | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

US Oncology, BioMarin Partner on Phase III BMN 673 Study

To investigate safety and effectiveness in breast cancer with BRCA1 or BRCA2 gene mutations

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

US Oncology Research is collaborating with BioMarin Pharmaceutical on a Phase III study to investigate the use of BMN 673, a PARP inhibitor, in metastatic breast cancer patients who test positive for BRCA1 or BRCA2 gene mutations. The study will investigate the effectiveness and safety of BMN 673. Thirteen U.S. Oncology Research affiliated practices with 56 locations will participate in the study.
 
The Phase III, open-label, randomized, parallel, 2-arm, multi-center study of BMN 673 versus physician’s choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer, who have received no more than two prior chemotherapy regimens for metastatic disease, will investigate the drug’s effectiveness, evaluate its safety, and compare it to commonly used treatments. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters